AB-1015

AB-1015 is an autologous integrated circuit T (ICT) cell therapy engineered for the treatment of ovarian cancer and related gynecologic malignancies. Developed by ArsenalBio, AB-1015 uses a precise CRISPR-based insertion of a large synthetic double-stranded DNA cassette into a safe harbor site on Chromosome 11. This cassette encodes two main features: 1. A synthetic "AND" logic gate that requires co-expression of two tumor antigens (ALPG/P and mesothelin) to activate the T cells, thereby limiting off-tumor toxicity. 2. A module containing short hairpin RNAs targeting FAS and PTPN2 to resist tumor microenvironment suppression and enhance T cell function. The therapy is designed to improve specificity for tumor cells while sparing normal tissues and overcoming immunosuppressive mechanisms in the tumor microenvironment. AB-1015 is currently being evaluated in phase I clinical trials for platinum-resistant ovarian cancer, fallopian tube cancer, and peritoneal cancer[1][2][3][4][8].

Other names

ab-x2157-n-700-pma